Patient-reported outcomes: what really matters to patients?
- PMID: 35489342
- DOI: 10.1016/S1470-2045(22)00156-5
Patient-reported outcomes: what really matters to patients?
Conflict of interest statement
EH reports research grants from Conquer Cancer Foundation and the Kidney Cancer Association and a scholarship from the International Kidney Cancer Coalition unrelated to this Correspondence, and an honorarium from Targeted Oncology. AMS reports an educational grant from Janssen Cilag and conference support from Novartis. All other authors declare no competing interests.
Comment in
-
Patient-reported outcomes: what really matters to patients? - Authors' reply.Lancet Oncol. 2022 May;23(5):e199. doi: 10.1016/S1470-2045(22)00216-9. Lancet Oncol. 2022. PMID: 35489343 No abstract available.
Comment on
-
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.Lancet Oncol. 2022 Feb;23(2):292-303. doi: 10.1016/S1470-2045(21)00693-8. Epub 2022 Jan 12. Lancet Oncol. 2022. PMID: 35032437 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources